» Articles » PMID: 36768152

Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer

Abstract

Circulating exosomes in the blood are promising tools for biomarker discovery in cancer. Due to their heterogeneity, different isolation methods may enrich distinct exosome cargos generating different omic profiles. In this study, we evaluated the effects of plasma exosome isolation methods on detectable multi-omic profiles in patients with non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC), and healthy controls, and developed an algorithm to quantify exosome enrichment. Plasma exosomes were isolated from CRPC (n = 10), NSCLC (n = 14), and healthy controls (n = 10) using three different methods: size exclusion chromatography (SEC), lectin binding, and T-cell immunoglobulin domain and mucin domain-containing protein 4 (TIM4) binding. Molecular profiles were determined by mass spectrometry of extracted exosome fractions. Enrichment analysis of uniquely detected molecules was performed for each method with MetaboAnalyst. The exosome enrichment index (EEI) scores methods based on top differential molecules between patient groups. The lipidomic analysis detected 949 lipids using exosomes from SEC, followed by 246 from lectin binding and 226 from TIM4 binding. The detectable metabolites showed SEC identifying 191 while lectin binding and TIM4 binding identified 100 and 107, respectively. When comparing uniquely detected molecules, different methods showed preferential enrichment of different sets of molecules with SEC enriching the greatest diversity. Compared to controls, SEC identified 28 lipids showing significant difference in NSCLC, while only 1 metabolite in NSCLC and 5 metabolites in CRPC were considered statistically significant (FDR < 0.1). Neither lectin-binding- nor TIM4-binding-derived exosome lipids or metabolites demonstrated significant differences between patient groups. We observed the highest EEI from SEC in lipids (NSCLC: 871.33) which was also noted in metabolites. These results support that the size exclusion method of exosome extraction implemented by SBI captures more heterogeneous exosome populations. In contrast, lectin-binding and TIM4-binding methods bind surface glycans or phosphatidylserine moieties of the exosomes. Overall, these findings suggest that specific isolation methods select subpopulations which may significantly impact cancer biomarker discovery.

Citing Articles

Extracellular Microvesicle MicroRNAs and Imaging Metrics Improve the Detection of Aggressive Prostate Cancer: A Pilot Study.

Avasthi K, Choi J, Glushko T, Manley B, Yu A, Park J Cancers (Basel). 2025; 17(5).

PMID: 40075682 PMC: 11898942. DOI: 10.3390/cancers17050835.


Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.

Zheng L, Chang R, Liang B, Wang Y, Zhu Y, Jia Z Cancer Drug Resist. 2025; 7():50.

PMID: 39802949 PMC: 11724354. DOI: 10.20517/cdr.2024.107.


Comparative proteomic analysis between tumor tissues and intratumoral exosomes from lung adenocarcinoma patients identifies PAFAH1B3 as an exosomal protein key for initiating metastasis in lung adenocarcinoma.

Wang C, Xiao L, Gao L, Wu J, Wang S, Zheng M Heliyon. 2024; 10(21):e39859.

PMID: 39553628 PMC: 11567031. DOI: 10.1016/j.heliyon.2024.e39859.


Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer.

Luo B, Que Z, Lu X, Qi D, Qiao Z, Yang Y Biol Proced Online. 2023; 25(1):29.

PMID: 37953280 PMC: 10641949. DOI: 10.1186/s12575-023-00223-0.

References
1.
Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

2.
. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

3.
Logozzi M, Mizzoni D, Di Raimo R, Fais S . Exosomes: A Source for New and Old Biomarkers in Cancer. Cancers (Basel). 2020; 12(9). PMC: 7565506. DOI: 10.3390/cancers12092566. View

4.
LeBleu V, Kalluri R . Exosomes as a Multicomponent Biomarker Platform in Cancer. Trends Cancer. 2020; 6(9):767-774. DOI: 10.1016/j.trecan.2020.03.007. View

5.
Kalluri R, LeBleu V . The biology function and biomedical applications of exosomes. Science. 2020; 367(6478). PMC: 7717626. DOI: 10.1126/science.aau6977. View